vs

Side-by-side financial comparison of Holley Inc. (HLLY) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

Holley Inc. is the larger business by last-quarter revenue ($155.4M vs $140.6M, roughly 1.1× VERACYTE, INC.). VERACYTE, INC. runs the higher net margin — 29.3% vs 4.1%, a 25.2% gap on every dollar of revenue. On growth, VERACYTE, INC. posted the faster year-over-year revenue change (18.5% vs 11.0%). VERACYTE, INC. produced more free cash flow last quarter ($48.8M vs $3.8M). Over the past eight quarters, VERACYTE, INC.'s revenue compounded faster (20.5% CAGR vs -1.0%).

Holley Performance Products is an automotive performance company based in Bowling Green, Kentucky. It was founded in 1896 in Bradford, Pennsylvania, by George Holley and Earl Holley. When the company was based in Michigan it was a major producer of carburetors for many Detroit-built automobiles.

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

HLLY vs VCYT — Head-to-Head

Bigger by revenue
HLLY
HLLY
1.1× larger
HLLY
$155.4M
$140.6M
VCYT
Growing faster (revenue YoY)
VCYT
VCYT
+7.6% gap
VCYT
18.5%
11.0%
HLLY
Higher net margin
VCYT
VCYT
25.2% more per $
VCYT
29.3%
4.1%
HLLY
More free cash flow
VCYT
VCYT
$45.0M more FCF
VCYT
$48.8M
$3.8M
HLLY
Faster 2-yr revenue CAGR
VCYT
VCYT
Annualised
VCYT
20.5%
-1.0%
HLLY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HLLY
HLLY
VCYT
VCYT
Revenue
$155.4M
$140.6M
Net Profit
$6.3M
$41.1M
Gross Margin
46.8%
72.5%
Operating Margin
12.7%
26.4%
Net Margin
4.1%
29.3%
Revenue YoY
11.0%
18.5%
Net Profit YoY
116.7%
704.8%
EPS (diluted)
$0.06
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HLLY
HLLY
VCYT
VCYT
Q4 25
$155.4M
$140.6M
Q3 25
$138.4M
$131.9M
Q2 25
$166.7M
$130.2M
Q1 25
$153.0M
$114.5M
Q4 24
$140.1M
$118.6M
Q3 24
$134.0M
$115.9M
Q2 24
$169.5M
$114.4M
Q1 24
$158.6M
$96.8M
Net Profit
HLLY
HLLY
VCYT
VCYT
Q4 25
$6.3M
$41.1M
Q3 25
$-806.0K
$19.1M
Q2 25
$10.9M
$-980.0K
Q1 25
$2.8M
$7.0M
Q4 24
$-37.8M
$5.1M
Q3 24
$-6.3M
$15.2M
Q2 24
$17.1M
$5.7M
Q1 24
$3.7M
$-1.9M
Gross Margin
HLLY
HLLY
VCYT
VCYT
Q4 25
46.8%
72.5%
Q3 25
43.2%
69.2%
Q2 25
41.7%
69.0%
Q1 25
41.9%
69.5%
Q4 24
45.6%
66.4%
Q3 24
39.0%
68.2%
Q2 24
41.5%
68.1%
Q1 24
32.8%
64.5%
Operating Margin
HLLY
HLLY
VCYT
VCYT
Q4 25
12.7%
26.4%
Q3 25
11.5%
17.4%
Q2 25
16.5%
-4.0%
Q1 25
12.6%
2.5%
Q4 24
-20.7%
3.5%
Q3 24
4.2%
10.4%
Q2 24
16.4%
4.0%
Q1 24
6.4%
-4.8%
Net Margin
HLLY
HLLY
VCYT
VCYT
Q4 25
4.1%
29.3%
Q3 25
-0.6%
14.5%
Q2 25
6.5%
-0.8%
Q1 25
1.8%
6.2%
Q4 24
-27.0%
4.3%
Q3 24
-4.7%
13.1%
Q2 24
10.1%
5.0%
Q1 24
2.4%
-1.9%
EPS (diluted)
HLLY
HLLY
VCYT
VCYT
Q4 25
$0.06
$0.50
Q3 25
$-0.01
$0.24
Q2 25
$0.09
$-0.01
Q1 25
$0.02
$0.09
Q4 24
$-0.32
$0.07
Q3 24
$-0.05
$0.19
Q2 24
$0.14
$0.07
Q1 24
$0.03
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HLLY
HLLY
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$37.2M
$362.6M
Total DebtLower is stronger
$516.1M
Stockholders' EquityBook value
$448.9M
$1.3B
Total Assets
$1.2B
$1.4B
Debt / EquityLower = less leverage
1.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HLLY
HLLY
VCYT
VCYT
Q4 25
$37.2M
$362.6M
Q3 25
$50.7M
$315.6M
Q2 25
$63.8M
$219.5M
Q1 25
$39.1M
$186.1M
Q4 24
$56.1M
$239.1M
Q3 24
$50.8M
$274.1M
Q2 24
$53.1M
$235.9M
Q1 24
$41.1M
$209.2M
Total Debt
HLLY
HLLY
VCYT
VCYT
Q4 25
$516.1M
Q3 25
$528.9M
Q2 25
$543.3M
Q1 25
$551.3M
Q4 24
$545.4M
Q3 24
$556.4M
Q2 24
$556.1M
Q1 24
$567.6M
Stockholders' Equity
HLLY
HLLY
VCYT
VCYT
Q4 25
$448.9M
$1.3B
Q3 25
$439.7M
$1.3B
Q2 25
$437.8M
$1.2B
Q1 25
$424.6M
$1.2B
Q4 24
$421.2M
$1.2B
Q3 24
$458.7M
$1.2B
Q2 24
$463.2M
$1.1B
Q1 24
$444.9M
$1.1B
Total Assets
HLLY
HLLY
VCYT
VCYT
Q4 25
$1.2B
$1.4B
Q3 25
$1.2B
$1.4B
Q2 25
$1.2B
$1.3B
Q1 25
$1.1B
$1.3B
Q4 24
$1.1B
$1.3B
Q3 24
$1.2B
$1.3B
Q2 24
$1.2B
$1.2B
Q1 24
$1.2B
$1.2B
Debt / Equity
HLLY
HLLY
VCYT
VCYT
Q4 25
1.15×
Q3 25
1.20×
Q2 25
1.24×
Q1 25
1.30×
Q4 24
1.29×
Q3 24
1.21×
Q2 24
1.20×
Q1 24
1.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HLLY
HLLY
VCYT
VCYT
Operating Cash FlowLast quarter
$6.2M
$52.6M
Free Cash FlowOCF − Capex
$3.8M
$48.8M
FCF MarginFCF / Revenue
2.4%
34.7%
Capex IntensityCapex / Revenue
1.5%
2.7%
Cash ConversionOCF / Net Profit
0.98×
1.28×
TTM Free Cash FlowTrailing 4 quarters
$33.9M
$126.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HLLY
HLLY
VCYT
VCYT
Q4 25
$6.2M
$52.6M
Q3 25
$7.4M
$44.8M
Q2 25
$40.5M
$33.6M
Q1 25
$-7.8M
$5.4M
Q4 24
$4.1M
$24.5M
Q3 24
$-1.7M
$30.0M
Q2 24
$25.7M
$29.6M
Q1 24
$18.8M
$-9.0M
Free Cash Flow
HLLY
HLLY
VCYT
VCYT
Q4 25
$3.8M
$48.8M
Q3 25
$5.3M
$42.0M
Q2 25
$35.7M
$32.3M
Q1 25
$-10.8M
$3.5M
Q4 24
$1.7M
$20.4M
Q3 24
$-3.5M
$27.7M
Q2 24
$24.3M
$26.8M
Q1 24
$17.6M
$-11.1M
FCF Margin
HLLY
HLLY
VCYT
VCYT
Q4 25
2.4%
34.7%
Q3 25
3.8%
31.8%
Q2 25
21.4%
24.8%
Q1 25
-7.1%
3.1%
Q4 24
1.2%
17.2%
Q3 24
-2.6%
23.9%
Q2 24
14.3%
23.4%
Q1 24
11.1%
-11.5%
Capex Intensity
HLLY
HLLY
VCYT
VCYT
Q4 25
1.5%
2.7%
Q3 25
1.6%
2.1%
Q2 25
2.9%
1.0%
Q1 25
1.9%
1.6%
Q4 24
1.7%
3.5%
Q3 24
1.3%
1.9%
Q2 24
0.8%
2.4%
Q1 24
0.8%
2.2%
Cash Conversion
HLLY
HLLY
VCYT
VCYT
Q4 25
0.98×
1.28×
Q3 25
2.34×
Q2 25
3.73×
Q1 25
-2.79×
0.76×
Q4 24
4.80×
Q3 24
1.98×
Q2 24
1.50×
5.16×
Q1 24
5.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HLLY
HLLY

Truck Off Road$125.5M81%
Euro Import$29.9M19%

VCYT
VCYT

Testing$135.8M97%
Products$3.8M3%
Biopharmaceutical And Other$686.0K0%

Related Comparisons